Tiziana Life Sciences LtdTLSA
Price (close)
$1.04
Market cap
$125.3M
P/E
—
Revenue (FY)
—
Net income
-$11.9M
Dividend yield
—
1-year total return
-49.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Tiziana Life Sciences Ltd does.
clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and neuroinflammatory
diseases. Our clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy,
Alzheimer’s, and Amyotrophic lateral sclerosis. Tiziana is led by a team of highly qualified executives with extensive drug development
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net income | -$9.3M | -$26.1M | -$23.4M | -$15.4M | -$17.7M | -$11.9M |
| Free cash flow | -$6.8M | -$11.3M | -$21.8M | — | — | -$1.5M |
More on TLSA.
- Tiziana Life Sciences Ltd summary
- Tiziana Life Sciences Ltd financial statements
- Tiziana Life Sciences Ltd key metrics
- Tiziana Life Sciences Ltd health scores and style box
- Tiziana Life Sciences Ltd earnings
- Tiziana Life Sciences Ltd dividends
- Tiziana Life Sciences Ltd valuation
- Tiziana Life Sciences Ltd ownership and insiders
- Tiziana Life Sciences Ltd peers
Figures from Tiziana Life Sciences Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.